The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose (Q37896606)

25 August 2017

1 reference

title

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose (English)

1 reference

25 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Giuliana Alimena

1 reference

25 August 2017

Massimo Breccia

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

2075-2087

1 reference

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Getting to the stem of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Critical role for Gab2 in transformation by BCR/ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597741

10.1517/14656566.2011.597741

21 January 2018

Identifiers

DOI

1 reference

release_7dxlfuafq5entob6qu3eferwzy

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7dxlfuafq5entob6qu3eferwzy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference